Europe Recombinant Albumin Market Analysis and Forecast by Size, Share, Growth, Trends 2031

The Europe Recombinant Albumin Market size is expected to reach US$ 169,684.1 Million by 2031 from US$ 88,666.7 Million in 2024. The market is estimated to record a CAGR of 9.7% from 2025 to 2031.

Executive Summary and Europe Recombinant Albumin Market Analysis:

Regulatory guidance in Europe is increasingly favoring alternatives to plasma-derived albumin. The 2004 position statement by the European Medicines Agency (EMA) encourages the development of alternatives to plasma-derived albumin when it is used as an excipient or in manufacturing processes. Furthermore, in September 2023, the EMA clarified in their Q&A for biologics that non-novel excipients manufactured via recombinant technology require detailed manufacturing, characterization, and viral-safety data, making recombinant albumin more accessible and transparent for developers. Additionally, according to the National Center for Biotechnology Information (NCBI, 2022), by October 2022, the EMA had authorized sixteen gene therapies, three cell therapies, and four tissue-engineered products under the ATMP umbrella, driving demand for high-quality, defined excipients. New product developments targeting GMP-grade, animal-free recombinant human serum albumin have also emerged in Europe, offering safer and more reliable alternatives to plasma-derived albumin. Thus, regulatory endorsements, growing biologics manufacturing needs, and innovative product launches altogether drive the adoption of recombinant albumin in Europe.

Europe Recombinant Albumin Market: Strategic Insights

Europe Recombinant Albumin Market Segmentation Analysis:

• By Source, the Europe Recombinant Albumin Market is segmented into Human Recombinant Albumin, Bovine Recombinant Albumin, and Other Sources. The Human Recombinant Albumin segment dominated the market in 2024.
• By Application, the Europe Recombinant Albumin Market is segmented into Excipient in Biotherapeutics and Vaccines, Cell Culture, Drug Delivery, Diagnostics, and Other Applications. The Excipient in Biotherapeutics and Vaccines segment dominated the market in 2024.
• By End User, the Europe Recombinant Albumin Market is segmented into Pharmaceutical and Biotechnology Companies, Research Institutes, Hospitals and Diagnostic Laboratories, and Others End Users. The Pharmaceutical and Biotechnology Companies segment dominated the market in 2024.

Europe Recombinant Albumin Market Players Density: Understanding Its Impact on Business Dynamics

The Europe Recombinant Albumin Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Europe Recombinant Albumin Market Outlook

Albumin remains a cornerstone in managing hypovolemia, burns, sepsis, and shock, conditions that have seen rising prevalence worldwide. According to the European Society of Intensive Care Medicine (ESICM), sepsis affected over forty-nine million people globally in 2022, with mortality rates exceeding 25% in some regions. The COVID-19 pandemic further underscored the importance of albumin therapies, as COVID-19 patients are often affected by hypoalbuminemia, necessitating albumin supplementation. Recent clinical trials in 2023, published in The Lancet, demonstrated improved survival rates in critically ill patients receiving recombinant albumin, encouraging broader clinical adoption. Moreover, the development of ready-to-use recombinant albumin formulations enhances ease of administration during emergencies, reducing risks of contamination and transfusion reactions. Governments and health agencies, including the U.S. FDA and European Medicines Agency, are increasingly approving recombinant albumin products for use in intensive care units (ICUs), reflecting a shift toward safer, standardized treatments. This persistent demand in high-acuity healthcare settings underscores the vital role of recombinant albumin in critical care.

Also, Albumin is widely employed in ICU settings for the treatment of sepsis, hypovolemic conditions, complications due to liver issues, kidney replacement treatments, and several other acute diseases. In line with a recently released guideline on the ScienceDirect website, CHEST Journal (August 2024), the prevalence of hypoalbuminemia is high in both acute and chronic conditions, contributing to mortality rates, thus highlighting the significance of treatments involving albumin in clinical practice. The growing application of albumin in the treatment protocols of critical care and emergency services will drive growth in the recombinant albumin market in the long run.

Europe Recombinant Albumin Market Country Insights

By country, the Europe Recombinant Albumin Market is segmented into Germany, the United Kingdom, France, Spain, Italy, and the Rest of Europe. Germany held the largest share in 2024.

The recombinant albumin market in Germany is driven by increasing medical needs and advancements in biopharmaceuticals. According to the Robert Koch Institute (RKI), the prevalence of liver diseases, burns, and critical care conditions requiring albumin therapy has been rising, with over 20,000 new liver cirrhosis cases reported in Germany in 2022. Germany has stringent regulations emphasizing product safety and ethical sourcing, which favor recombinant over plasma-derived products. In 2023, the German Federal Institute for Drugs and Medical Devices (BfArM) approved new recombinant albumin formulations that offer improved safety profiles and reduced risk of pathogen transmission, aligning with Europe-wide regulatory trends. Additionally, ongoing research and collaborations between biotech firms and academic institutions have led to innovative formulations, including recombinant albumin for use in critical care and surgical applications. The COVID-19 pandemic further highlighted the importance of reliable, pathogen-free biopharmaceuticals, spurring investments and regulatory support for recombinant products. As of 2024, regulatory agencies in Germany continued to endorse recombinant albumin for its safety and sustainability, driving its adoption across healthcare facilities.

Europe Recombinant Albumin Market Company Profiles

Some of the key players operating in the market include Thermo Fisher Scientific Inc, CSL Ltd, Merck KGaA, Sartorius AG, Akron Biotech, HiMedia Laboratories Pvt Ltd, InVitria, Medxbio Pte Ltd, Lazuline Biotech Private Limited, and Cyagen Biosciences.

These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

Europe Recombinant Albumin Market Research Methodology

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations
• Industry trade journals and other relevant publications
• Government documents, statistical databases, and market reports
• News articles, press releases, and webcasts specific to companies operating in the market

Note: All financial data included in the Company Profiles section has been standardized to US$. For companies reporting in other currencies, figures have been converted to US$ using the relevant exchange rates for the corresponding year.

Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research
• Enhance the expertise and market understanding of the analysis team
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, Business Development Managers, Market Intelligence Managers, and National Sales Managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise